Clinical trials: Beta Endorphin
Membranous Nephropathy
Adrenocorticotropic Hormone in Membranous Nephropathy
The purpose of this study is to evaluate the effect of adrenocorticotropic hormone (ACTH, Acthar) on the loss of proteins in the urine (proteinuria) in patients with membranous nephropathy.
- Trial name
- NCT03025828
- Testing
- ACTHar
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Covid Patients
Beta Endorphins,Interleukin 1 and Interleukin 38 in Covid Patients Associated With Neuropsychological Manifestations.
Measurement of Beta endorphins,interleukin 1 and interleukin 38 in covid patients associated with neuropsychological manifestations.
- Trial name
- NCT05198388
- Testing
- βeta endorphins, interleukin 6 and interleukin 38
- Where
- Egypt
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assiut University
Cushings Disease
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing's disease.
- Trial name
- NCT01915303
- Testing
- Pasireotide with or without cabergoline
- Where
- 29 sites in United States, Argentina and 14 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Effect of Ketoconazole on Breathlessness
Beta-endorphins, which are naturally occurring narcotic substances, have been shown to alter the perception of breathlessness. Oral ketoconazole, an antifungal antibiotic, increases blood levels of beta-endorphins.
- Trial name
- KetoRLB (NCT01378520)
- Testing
- ketoconazole, inert powder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Cushing's Syndrome
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
- Trial name
- SEISMIC (NCT00569582)
- Testing
- mifepristone
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Cushing's Syndrome
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome.
- Trial name
- NCT00936741
- Testing
- mifepristone
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corcept Therapeutics
Brain Injury, Craniocerebral Trauma
Study of the Approximate Entropy of Adrenocorticotropic Hormone and Cortisol Secretion in Patients With Head Injury
OBJECTIVES: I. Determine the randomness of adrenocorticotropic hormone (ACTH) and cortisol secretion using approximate entropy in patients who have sustained a head injury. II.
- Trial name
- NCT00006270
- Testing
- cosyntropin, metyrapone
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Center for Research Resources (NCRR)
Healthy, Involutional Depression
Dynamics of Leptin and Endocrine Function
This is a study investigating the hormones and substances important to the stress response. The hormone that is most directly responsible for stress response is called corticotropin-releasing hormone (CRH).
- Trial name
- NCT00001543
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Patient Admitted in Reanimation
Hydrocortisone Use After Etomidate in Intensive Care
the objective of the study is to assess the value of substitution with 200mg/24h of hydrocortisone for 48 hours for patients in intensive care who have received a single injection of etomidate
- Trial name
- NCT00862381
- Testing
- Hydrocortisone
- Where
- 2 sites in France
- Volunteers
- 106 people
- Sponsor
- University Hospital, Grenoble
Multiple Sclerosis
Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS
The primary objective of this study is to determine if monthly pulse doses of a three-day course ACTH (H.P. Acthar®) is more effective at recovering myelin at 12 months, as measured by myelin water fraction (MWF), in new multiple…
- Trial name
- NCT02446886
- Testing
- Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Chronic Obstructive Pulmonary Disease
Differentiating the Effects of Substance P and Beta-endorphin
In previous studies we demonstrated that endogenous opioids (inhibitory neuropeptides) modulate the perception of breathing difficulty in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01854177
- Testing
- Aprepitant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Multiple Sclerosis
Evaluation of the Effects of Laughter Yoga
This randomized controlled study aims to evaluate the effects of laughter yoga on pain intensity, fatigue, and beta-endorphin levels in patients with Multiple Sclerosis.
- Trial name
- NCT07524231
- Testing
- Laughter Yoga
- Where
- Turkey (Türkiye)
- Volunteers
- 72 people
- Sponsor
- Firat University
Adrenal Sufficiency
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein
Males and females may exhibit different responses to testing of adrenal function. The hormones responsible for controlling adrenal function are ACTH (adrenocorticotropic hormone or corticotropin) and CRH (corticotropin-releasing…
- Trial name
- NCT00196001
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City
Adrenal Incidentaloma, Subclinical Hypercortisolism
Evaluation of New Diagnostic Indicator of Subclinical Hypercortisolism
The purpose of this study is to evaluate the serum dehydroepiandrosterone sulfate in subclinical hypercortisolism
- Trial name
- NCT04833192
- Testing
- experimental group
- Where
- China
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics